Loading…
Sonoma Pharmaceuticals, Inc. is projected to rise to $1.17 by 2027, a +5% move from its current price of $1.12. SNOA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.09 | $1.12 | $1.15 | -0.05% |
| Aug 6 | $1.08 | $1.12 | $1.16 | -0.11% |
| Aug 7 | $1.07 | $1.12 | $1.16 | -0.16% |
| Aug 8 | $1.07 | $1.12 | $1.17 | -0.22% |
| Aug 9 | $1.06 | $1.12 | $1.18 | -0.27% |
| Aug 10 | $1.06 | $1.12 | $1.18 | -0.33% |
| Aug 11 | $1.05 | $1.12 | $1.18 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.05 | $1.12 | $1.18 | -0.38% |
| Week 2 | $1.02 | $1.11 | $1.21 | -0.77% |
| Week 3 | $0.9976 | $1.11 | $1.23 | -1.15% |
| Week 4 | $0.9778 | $1.10 | $1.24 | -1.53% |
| Week 5 | $0.9603 | $1.10 | $1.26 | -1.91% |
| Week 6 | $0.9445 | $1.09 | $1.27 | -2.28% |
| Week 7 | $0.9298 | $1.09 | $1.28 | -2.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. Incorporated in 1999, the company is based in Boulder, Colorado.
It was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016.
Its portfolio includes Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fissures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, Ocucyn, Ocudox, Sinudox, Microdacyn60, Podiacyn, MicrocynAH, MicrocynVS, Nanocyn, Acuicyn, MucoClyns, and Endocyn, all HOCl-based products designed for healing, hygiene, and disinfection across multiple markets.
Sonoma Pharmaceuticals is a micro-cap stock with current price $1.16 and market cap $5.72M, ranked 5488. The near-term outlook centers on a current price that aligns with the 50-day moving average of $1.16 while trading below the 200-day moving average of $2.57, signaling limited upside near term. The longer-run forecast shows gradual upside with a path from a 2026 average of $1.16 toward higher levels by 2030 and beyond, including a 2050 average of $3.21 and a 176.8 ROI at the far end of the horizon.
A major floor 11.3% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.8% away) — a key level to hold.
The nearest ceiling, 12.5% above — a clean break opens room to run.
A major ceiling 136.6% above — clearing it would confirm fresh momentum.
Key SNOA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNOA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.12 | Sell | $1.12 | Sell |
| MA 10 | $1.14 | Sell | $1.14 | Sell |
| MA 20 | $1.19 | Sell | $1.16 | Sell |
| MA 50 | $1.16 | Sell | $1.25 | Sell |
| MA 100 | $1.52 | Sell | $1.59 | Sell |
| MA 200 | $2.46 | Sell | $2.16 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.62 | Neutral |
| Stoch RSI (14) | 13.04 | Buy |
| CCI (20) | -128.83 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -9.84 | Sell |
| Bollinger %B (20,2) | 0.06 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.06 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 29.40 | Buy |
| Momentum (10) | -0.11 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 1.10 | Buy |
| ADX (14) | 15.13 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is Neutral, with RSI14 at 40. The 50-day simple moving average is $1.16 and the 200-day simple moving average is $2.57. Support is at $1.09 and resistance at $1.26, placing near-term price action within a modest range. The 30-day trading range spans from a low of $0.9839 to a high of $1.37.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.01 | $1.12 | $1.26 | 0% | Neutral | |
| $0.9502 | $1.17 | $1.52 | +5% | Neutral | |
| $1.02 | $1.28 | $1.72 | +15% | Neutral | |
| $1.00 | $1.29 | $1.77 | +15% | Neutral | |
| $1.02 | $1.33 | $1.87 | +19% | Neutral | |
| $0.9714 | $1.29 | $1.85 | +15% | Neutral | |
| $0.9597 | $1.29 | $1.88 | +16% | Neutral | |
| $0.998 | $1.36 | $2.01 | +22% | Bullish | |
| $1.12 | $1.55 | $2.31 | +38% | Bullish | |
| $1.21 | $1.70 | $2.58 | +52% | Bullish | |
| $1.44 | $2.13 | $3.40 | +90% | Bullish | |
| $1.87 | $3.03 | $5.24 | +170% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.01 | $1.12 | $1.28 | +0.00% |
| September 2026 | $0.8958 | $1.05 | $1.27 | -5.88% |
| October 2026 | $0.9001 | $1.07 | $1.30 | +1.05% |
| November 2026 | $0.8811 | $1.05 | $1.28 | -1.65% |
| December 2026 | $0.854 | $1.02 | $1.26 | -2.66% |
Click any year to see its month-by-month SNOA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sonoma Pharmaceuticals, Inc.'s 2026 outlook centres on $1.12, within a $1.01 to $1.26 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, SNOA could reach as high as $1.52, with a base case around $1.17 and support toward $0.9502 — roughly +5% from $1.12. A consolidation phase looks the most probable path here.
Expect SNOA to range from $1.02 to $1.72 through 2028. The $1.28 average target implies a +15% move from current prices. That is up +9% on the projected 2027 average. Price action looks broadly range-bound.
The SNOA price prediction for 2029 points to an average of $1.29 (low $1.00, high $1.77) — a potential gain of +15% on today's $1.12. A consolidation phase looks the most probable path here.
In 2030, SNOA is projected to trade between $1.02 and $1.87, averaging $1.33 — a potential gain of +19% from today's $1.12. That is up +3% on the projected 2029 average. Price action looks broadly range-bound.
Sonoma Pharmaceuticals, Inc.'s 2031 outlook centres on $1.29, within a $0.9714 to $1.85 range. That is -3% versus the projected 2030 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, SNOA could reach as high as $1.88, with a base case around $1.29 and support toward $0.9597 — roughly +16% from $1.12. Price action looks broadly range-bound.
Expect SNOA to range from $0.998 to $2.01 through 2033. The $1.36 average target implies a +22% move from current prices. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The SNOA price prediction for 2034 points to an average of $1.55 (low $1.12, high $2.31) — a potential gain of +38% on today's $1.12. Momentum favours further upside here.
In 2035, SNOA is projected to trade between $1.21 and $2.58, averaging $1.70 — a potential gain of +52% from today's $1.12. That is up +10% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Sonoma Pharmaceuticals, Inc.'s 2040 outlook centres on $2.13, within a $1.44 to $3.40 range. That is up +25% on the projected 2035 average. That marks a +90% change versus current levels. Momentum favours further upside here.
By 2050, SNOA could reach as high as $5.24, with a base case around $3.03 and support toward $1.87 — roughly +170% from $1.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in SNOA today (≈ 892.857143 SNOA) could be worth
$2,702
+$1,702 (+170%) by 2050 · US Dollar
Based on the average projected SNOA price of $3.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNOAwould be worth at today's price.
$1,000 invested in SNOA on Jul 31, 2025 (≈ 335.570468 SNOA) would be worth
$375.84
-$624.16 (-62.4%) today · 0.38× · US Dollar
Based on a SNOA entry price of $2.98 vs. today's $1.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.14 | $982.46 | -1.8% |
| 1 month ago | $1.21 | $925.62 | -7.4% |
| 3 months ago | $1.2 | $933.33 | -6.7% |
| 6 months ago | $3.21 | $348.91 | -65.1% |
| 1 year ago | $2.98 | $375.84 | -62.4% |
| All time (5.0y) ago | $117.4 | $9.54 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNOA forecast.
Our base-case forecast reaches $2.20 around 2050.
Implied market cap at $2.20: $10.53M
The multi-year forecast lays out a gradual upward path. For 2026, the avg price is $1.16 with a min of $1.01 and a max of $1.31 and roiPct of 0, with NEUTRAL sentiment. The forecast then trends higher, with 2027 avg $1.25 and roiPct 7.6, 2028 avg $1.34 and roiPct 15.8, and 2029 avg $1.35 and roiPct 16.6, all NEUTRAL.
By 2030 the avg rises to $1.42 with min $1.07 and max $2.03 and roiPct 22.4, with a BULLISH sentiment. Further out, 2033 shows avg $1.46 and max $2.20 with roiPct 25.6 and BULLISH. 2034 offers avg $1.63 and max $2.50 with roiPct 40.8 and BULLISH, and 2035 shows avg $1.82 and max $2.82 with roiPct 56.8 and BULLISH.
The horizon extends to 2040 where avg is $2.25 and max $3.70 with roiPct 94.1 and BULLISH, and to 2050 with avg $3.21 and max $5.75 and roiPct 176.8 and BULLISH.
These are estimates of future performance and are not guarantees. Real-world results may vary, and the asset may experience higher volatility given its small market cap and the forecasted ranges.
Tap a question to reveal the answer.
2030: avg $1.42, min $1.07, max $2.03; roiPct 22.4; sentiment BULLISH.
The forecast shows potential long-run upside with 2050 avg $3.21 and roiPct 176.8, but near-term metrics indicate a flat path around $1.16 in 2026 (avg) with roiPct 0 and NEUTRAL sentiment, and the stock exhibits notable volatility (annualized volatility around 50). These are estimates, not guarantees.
Yes. The 2030 max is $2.03, the 2040 max is $3.70, and the 2050 max is $5.75, indicating potential upside beyond $2 at later horizons.
Current price $1.16; market cap $5.72M.
30-day range low $0.9839, high $1.37.
Sonoma Pharmaceuticals, Inc. Community Discussion
0Share your Sonoma Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.